Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4066 AL 4080

Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease

Fernandes TB, Cunha MR, Sakata RP, Candido TM, Baby AR, Tavares MT, Barbosa EG, Almeida WP, Parise-Filho R.

Arch Pharm (Weinheim). 2017 Nov;350(11). doi: 10.1002/ardp.201700163. Epub 2017 Sep 22.

The role of the immune system in Alzheimer disease: Etiology and treatment

Jevtic S, Sengar AS, Salter MW, McLaurin J.

Ageing Res Rev. 2017 Nov;40:84-94. doi: 10.1016/j.arr.2017.08.005. Epub 2017 Sep 21.

Therapeutic peptides for CNS indications: Progress and challenges

Morimoto BH.

Bioorg Med Chem. 2018 Jun 1;26(10):2859-2862. doi: 10.1016/j.bmc.2017.09.011. Epub 2017 Sep 9.

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise

van Dyck CH.

Biol Psychiatry. 2018 Feb 15;83(4):311-319. doi: 10.1016/j.biopsych.2017.08.010. Epub 2017 Aug 24.

Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease

Kaushik V, Smith ST, Mikobi E, Raji MA.

Am J Alzheimers Dis Other Demen. 2018 Mar;33(2):73-85. doi: 10.1177/1533317517734352. Epub 2017 Oct 3.

The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review

Anand A, Patience AA, Sharma N, Khurana N.

Eur J Pharmacol. 2017 Nov 15;815:364-375. doi: 10.1016/j.ejphar.2017.09.043. Epub 2017 Oct 1.

Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine

Liu Q, Wang SC, Ding K.

Chin J Nat Med. 2017 Sep;15(9):641-652. doi: 10.1016/S1875-5364(17)30093-6.

Curcumin or bisdemethoxycurcumin for nose-to-brain treatment of Alzheimer disease? A bio/chemo-informatics case study

Hathout RM, El-Ahmady SH, Metwally AA.

Nat Prod Res. 2018 Dec;32(24):2873-2881. doi: 10.1080/14786419.2017.1385017. Epub 2017 Oct 12.

Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans

Griffin EF, Caldwell KA, Caldwell GA.

ACS Chem Neurosci. 2017 Dec 20;8(12):2596-2606. doi: 10.1021/acschemneuro.7b00361. Epub 2017 Oct 25.

Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?

Wu H.

Future Med Chem. 2017 Nov;9(17):1979-1981. doi: 10.4155/fmc-2017-0190. Epub 2017 Oct 27.

How efficient are rodent models for Alzheimer's disease drug discovery?

Guo B, Zhou Q.

Expert Opin Drug Discov. 2018 Feb;13(2):113-115. doi: 10.1080/17460441.2018.1398730. Epub 2017 Oct 31.

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group.

Lancet Neurol. 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0. Epub 2017 Oct 30.

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer's Disease

Ouyang QQ, Zhao S, Li SD, Song C.

Mar Drugs. 2017 Nov 7;15(11):322. doi: 10.3390/md15110322.

Editorial: Multi-target Drug Discovery - Part I

Chen JN.

Curr Top Med Chem. 2017;17(27):2997-2999. doi: 10.2174/156802661727171102165810.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias